Transcription Factor 7-Like 2 (TCF7L2) Polymorphism and Context-Specific Risk of Type 2 Diabetes in African American and Caucasian Adults: The Atherosclerosis Risk in Communities Study by Yan, Yu et al.
Transcription Factor 7-Like 2 (TCF7L2) Polymorphism
and Context-Speciﬁc Risk of Type 2 Diabetes in African
American and Caucasian Adults
The Atherosclerosis Risk in Communities Study
Yu Yan,
1 Kari E. North,
1,2 Christie M. Ballantyne,
3 Frederick L. Brancati,
4,5 Lloyd E. Chambless,
6
Nora Franceschini,
1 Gerardo Heiss,
1 Anna Kottgen,
4 James S. Pankow,
7 Elizabeth Selvin,
4
Suzanne L. West,
1 and Eric Boerwinkle
8
OBJECTIVE—Although variants in the transcription factor
7-like 2 (TCF7L2) gene are consistently associated with type 2
diabetes, large population-based studies of African Americans
are lacking. Moreover, few studies have investigated the effects
of TCF7L2 on type 2 diabetes in the context of metabolic risk
factors of type 2 diabetes.
RESEARCH DESIGN AND METHODS—We investigated the
association between the TCF7L2 rs7903146 polymorphism and type
2 diabetes in 2,727 African American and 9,302 Caucasian partici-
pants without diabetes who were inducted into the Atherosclerosis
Risk in Communities study in 1987–1989 and followed for 9 years.
RESULTS—A total of 485 and 923 cases of type 2 diabetes were
identiﬁed in African Americans and Caucasians, respectively.
Compared with homozygous CC individuals, heterozygous CT
and homozygous TT individuals had higher cumulative incidence
of type 2 diabetes over 9 years of follow-up: 11.3% (95% CI
10.2–12.4) vs. 21.1% (20.8–21.4) and 27.9% (19.3–36.5) in African
Americans, respectively, and 9.7% (8.8–10.6) vs. 11.3% (10.2–12.4)
and 13.6% (11.1–16.1), respectively, in Caucasians. Individuals
with the risk allele had the highest hazards of diabetes if they
were obese and had low HDL cholesterol, followed by individu-
als with any one and none of the traits.
CONCLUSIONS—Our study provides the ﬁrst signiﬁcant evi-
dence of association between the TCF7L2 rs7903146 polymor-
phism and type 2 diabetes risk in a large African American
population and also demonstrates that the diabetes risk con-
veyed by the rs7903146 risk allele is substantially increased in the
context of some metabolic risk factors for type 2 diabetes. Our
study ﬁndings need to be replicated in other large, population-
based studies. Diabetes 58:285–289, 2009
T
ype 2 diabetes is characterized by insulin resis-
tance and defects in insulin secretion as a result
of -cell dysfunction (1) resulting from the inter-
play of genetic and environmental factors (2).
The transcription factor 7-like 2 (TCF7L2) gene, a Wnt
signaling-associated transcription factor located on chro-
mosome 10q25, has emerged as a consistently replicated
susceptibility gene for type 2 diabetes (3–5). The T-allele at
single nucleotide polymorphism (SNP) rs7903146 has been
described as either the causal risk variant or the closest
correlate to an unidentiﬁed functional variant (6), possi-
bly impairing glucagon-like peptide-1–induced insulin se-
cretion (7), but the exact mechanism is still under
investigation.
Although the TCF7L2 effect is consistently observed
across ethnically diverse populations (3,4), studies con-
ducted in African Americans have been of small sample
size and results have been inconsistent (4–6,8,9). More-
over, TCF7L2 gene–environment interaction assessment
has been limited. Although previous studies have demon-
strated effect modiﬁcation by BMI (8,10), modiﬁcations by
other metabolic risk factors have been largely unexplored.
In this study, we investigated whether the rs7903146
SNP of the TCF7L2 gene is associated with type 2 diabetes
in a large community-based cohort of African American
and Caucasian middle-aged adults participating in the
Atherosclerosis Risk in Communities (ARIC) study. A
second objective was to evaluate whether the risk of type
2 diabetes was associated with the rs7903146 SNP in the
context of metabolic impairments.
RESEARCH DESIGN AND METHODS
Study subjects and phenotype deﬁnitions. The ARIC study is an ongoing
longitudinal cohort study of cardiovascular and other major diseases among
15,792 men and women aged 45–64 years at baseline (1987–1989) and selected
from four U.S. communities: Forsyth County, NC; Jackson, MS; the northwest-
ern suburbs of Minneapolis, MN; and Washington County, MD. By design,
African Americans were oversampled at the Forsyth County site and exclu-
sively sampled in Jackson and thus constituted 27% of the baseline cohort. The
sampling procedures and methods used in ARIC have been described in detail
elsewhere (11).
We excluded ARIC participants who were not African American or
Caucasian (n  48), African Americans from Minnesota and Maryland ﬁeld
centers (n  55), participants with prevalent diabetes (n  1,863), participants
with missing information on incident diabetes (n  1,026), and participants
with missing genotype data or who did not provide consent for the use of DNA
(n  771). After these exclusions, 12,029 baseline examination participants
(2,727 African Americans and 9,302 Caucasians) were available for analysis.
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Individuals were classiﬁed as diabetic if any of the following conditions
were met: fasting serum glucose levels 7.0 mmol/l (126 mg/dl), nonfasting
glucose levels 11.1 mmol/l (200 mg/dl), current use of hypoglycemic
medications (e.g., insulin or sulfonlyureas), or a self-reported physician
diagnosis of diabetes (12). Individuals without diabetes at baseline who
subsequently met any of these criteria at visit two, three, or four were
considered to have incident type 2 diabetes.
A positive family history of diabetes was deﬁned by participant report of
diabetes in either biological parent. Self-reported cigarette smoking was
deﬁned as ever smoking versus never smoking, and the information was
obtained by a personal interview. BMI was calculated as kilograms divided by
the square of height in meters. Individuals with a BMI 30 kg/m
2 were
classiﬁed as obese (13). Elevated waist circumference was deﬁned as waist
circumference 102 cm in men or 88 cm in women (14). Blood pressure at
baseline was measured three times using a random zero sphygmomanometer,
and the average of the last two measurements was used for this analysis.
Hypertension was deﬁned as systolic blood pressure 140 mmHg, diastolic
blood pressure 90 mmHg, or antihypertension medication use (15). Plasma
total cholesterol levels, HDL cholesterol, and triglyceride levels were mea-
sured by enzymatic methods, and LDL cholesterol was calculated (16). Low
HDL was deﬁned as 40 mg/dl in men and 50 mg/dl in women. High LDL was
deﬁned as 160 mg/dl, and high triglyceride levels were deﬁned as 200 mg/dl
(17). Insulin was measured by radioimmunoassay (
125Insulin Kit; Cambridge
Medical Diagnostics, Billerica, MA). Physical activity was quantiﬁed using a
slightly modiﬁed version of the Baecke physical activity questionnaire (18)
that classiﬁed work, sport, and leisure activities into categories ranging from
one (low) to ﬁve (high). Impaired fasting glucose was deﬁned by a fasting
glucose level between 100 and 125 mg/dl (19). Homeostasis model assessment
of insulin resistance (HOMA-IR) was calculated using the following formula:
fasting serum insulin (U/ml)  fasting glucose (mmol/l)/22.5 (20). Predicted
diabetes risk was deﬁned as the probability of developing diabetes over the
9-year follow-up period, which is predicted by a model that includes age at
baseline, race, parental history of diabetes, fasting glucose, systolic blood
pressure, waist circumference, height, HDL cholesterol, and triglycerides (21).
SNP genotyping. The TCF7L2 rs7903146 SNP was genotyped by the ARIC
central laboratory using Taqman assays (Applied Biosystems, Foster City,
CA). Laboratory-designed probes were obtained from Applied Bioystems and
primers from Integrated DNA Technologies (Coralville, IA). All PCR reactions
took place in optical 384-well reaction plates (Applied Biosystems). Five
percent of samples were regenotyped for quality control, and 726 ARIC
participants were genotyped in duplicate. The percent agreement was 98%,
and the simple  coefﬁcient was 0.97, indicating a good genotyping quality.
Statistical analysis. All analyses were stratiﬁed by race to crudely account
for population stratiﬁcation. To assess whether genotype distribution within
each race departed from Hardy-Weinberg equilibrium, a 
2 goodness-of-ﬁt test
was used. We estimated the predicted cumulative incidence/risk of type 2
diabetes over a 9-year follow-up using the Kaplan-Meier approach. We also
calculated the risk difference of type 2 diabetes by subtracting the risk among
the reference group (i.e., CC carriers) from the risk among the index group
(i.e., homozygous TT carriers). We used Cox proportional hazards modeling to
estimate the hazard ratios (HRs) and 95% CIs of incident diabetes. The hazard
function was formulated on the age scale, and date of diabetes onset was
interpolated using blood glucose levels at the visits at each end of the triennial
intervals (22). Covariates—including ever smoking, BMI, obesity, hyperten-
sion, HDL and LDL cholesterol, and work, sport, and leisure-time physical
activity level—were assessed as potential confounders and dismissed from all
further analyses. We compared heterozygous CT-genotype and homozygous
TT-genotype individuals with CC-genotype individuals, using the rs7903146
CC-genotype as the referent group and the T-allele as the risk variant.
TABLE 1
Selected characteristics of the ARIC study participants at baseline, presented by race and genotype status
African American Caucasian
CC CT TT P CC CT TT P
n 1,381 1,133 213 4,725 3,783 794
Age (years) 53 	 5.83 53 	 5.60 54 	 5.83 0.12 54 	 5.66 54 	 5.69 54 	 5.75 0.25
Sex (male) 500 (36.21) 447 (39.45) 81 (38.03) 0.25 2,188 (46.31) 1,746 (46.15) 379 (47.73) 0.71
Family diabetes
history 318 (23.03) 295 (26.04) 57 (26.76) 0.16 1,006 (21.29) 846 (22.36) 178 (22.42) 0.45
Predicted diabetes
risk* 0.23 	 0.20 0.20 	 0.19 0.25 	 0.22 0.01 0.15 	 0.15 0.16 	 0.16 0.17 	 0.15 0.27
Ever smoked 715 (51.77) 610 (53.89) 117 (54.93) 0.47 2,793 (59.14) 2,241 (59.27) 475 (59.82) 0.94
Leisure-time physical
activity 2.08 	 0.58 2.12 	 0.59 2.05 	 0.56 0.22 2.48 	 0.53 2.48 	 0.53 2.46 	 0.53 0.62
Obese 522 (37.80) 393 (34.75) 72 (33.80) 0.22 998 (21.12) 724 (19.16) 141 (17.76) 0.02
BMI (kg/m
2) 29.34 	 6.11 28.86 	 5.81 28.55 	 5.28 0.05 26.73 	 4.58 26.52 	 4.60 26.54 	 4.58 0.09
Waist circumference
(cm) 97.97 	 15.09 96.74 	 14.38 96.25 	 13.28 0.06 95.37 	 12.93 94.74 	 12.66 94.96 	 12.67 0.08
Hypertension 700 (51.02) 572 (50.66) 103 (48.58) 0.80 1,154 (24.57) 923 (24.51) 174 (22.03) 0.29
SBP (mmHg) 131.07 	 21.93 132.19 	 22.43 129.08 	 22.07 0.42 119.83 	 16.48 119.97 	 17.18 121.17 	 16.69 0.36
DBP (mmHg) 77.43 	 10.34 77.44 	 11.33 76.14 	 11.05 0.53 70.97 	 9.17 70.91 	 9.10 71.37 	 9.30 0.67
IFG 594 (44.30) 461 (42.25) 87 (41.83) 0.55 1,868 (40.20) 1,560 (41.97) 371 (47.63) 0.01
Glucose (mmol/l) 5.47 	 0.56 5.46 	 0.54 5.47 	 0.57 0.95 5.45 	 0.49 5.48 	 0.50 5.52 	 0.52 0.01
Insulin (U/ml) 13.82 	 10.67 12.79 	 8.78 12.62 	 8.68 0.02 10.24 	 7.60 9.83 	 7.27 9.88 	 8.10 0.04
HOMA-IR† 3.45 	 2.90 3.18 	 2.37 3.15 	 2.33 0.03 2.54 	 2.05 2.45 	 1.97 2.47 	 2.18 0.12
Triglycerides (mg/dl) 104.06 	 62.50 105.63 	 78.38 104.88 	 58.04 0.86 130.33 	 76.91 128.73 	 76.80 130.75 	 83.63 0.59
Low HDL 400 (29.59) 321 (28.92) 59 (28.37) 0.90 1,799 (38.13) 1,436 (38) 306 (38.59) 0.95
HDL (mg/dl) 56.51 	 17.77 56.45 	 17.96 55.48 	 17.23 0.74 51.41 	 16.78 51.75 	 16.95 51.10 	 16.50 0.49
LDL (mg/dl) 136.84 	 42.65 135.78 	 41.54 136.33 	 47.07 0.83 137.60 	 37.46 136.7 	 37.54 137.49 	 37.70 0.54
One metabolic risk
factor‡ 526 (38.56) 436 (39.03) 83 (39.71) 0.93 1,719 (36.43) 1,300 (34.42) 295 (37.20) 0.10
Two metabolic risk
factors‡ 198 (14.52) 139 (12.44) 24 (11.48) 0.24 539 (11.42) 430 (11.38) 76 (9.58) 0.30
Data are means 	 SE or n (%) unless otherwise indicated. *Probability of developing diabetes over the 9-year follow-up period was predicted
by a model including age at baseline, race, parental history of diabetes, fasting glucose, systolic blood pressure, waist circumference, height,
HDL cholesterol, and triglycerides (ref. 22). †Calculated as fasting serum insulin (U/ml)  fasting plasma glucose (mmol/l)/22.5 (ref. 21).
‡Metabolic risk factors refer to obesity or low HDL cholesterol. DBP, diastolic blood pressure; IFG, impaired fasting glucose; SBP, systolic
blood pressure.
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two for genotype TT were used to test for additive genetic effects.
The assessment of departure from additivity in gene-environment interac-
tion analyses has been argued to be more indicative of the underlying
biologically causal mechanisms than the assessment of multiplicative inter-
action (23). Among the three measures of additivity (the interaction contrast
ratio [ICR], proportion of disease attributable to interaction, and synergy
index), ICR performs best when using a proportional hazards model (24).
Variables were considered as potential effect-measure modiﬁers if either of
the following criteria were met: departures from additivity of effect as
assessed by the ICR (23) or an indication of context-speciﬁc effects in the
previous TCF7L2 literature. ICRs were quantiﬁed as follows: ICR  HR_AB 

HR_A 
 HR_B  1, where HR_AB represents the joint effect of metabolic
exposure and the SNP and HR_A and HR_B represent the main effects of
metabolic exposure and the SNP, respectively (23). Thus, ICR refers to the
increased risk due to additive interaction between metabolic risk factors and
the T-(risk) allele adjusted for age, sex, and study center. Assuming an
additive mode of inheritance, the ICR comparing TT with CT is equal to the
ICR comparing CT with CC where the metabolic exposure of interest is
constant; thus, only one ICR was reported. Departures from zero suggest that
the exposure of interest and the SNP interact to cause type 2 diabetes. The HR
and the variance-covariance matrix were used to calculate ICR values and
their 95% CIs (24). As our interaction analyses indicated obesity and low HDL
as possible effect modiﬁers, we further divided the ARIC population into three
mutually exclusive subgroups according to the presence of none, one (obesity
only or low HDL only), or both of these two metabolic risk factors.
RESULTS
Selected baseline characteristics of the ARIC study partic-
ipants without diabetes are presented by race and geno-
type status in Table 1. A total of 485 (17.8%) and 923 (9.9%)
incident type 2 diabetes cases were identiﬁed among
African American and Caucasian ARIC participants, re-
spectively (Table 2). The rs7903146 T-allele was observed
with similar frequency in African American and Caucasian
individuals but was more common among incident type 2
diabetes cases than noncases in both races (Table 2). The
risk of type 2 diabetes was highest among TT individuals,
followed by CT individuals, and lowest among CC individ-
uals in both races (Table 2). As previously documented,
the risk of type 2 diabetes was higher in African Americans
than in Caucasians with the same genotype.
We identiﬁed obesity and low HDL as important effect-
measure modiﬁers, although 95% CIs of some individual
ICRs were wide (Table 3; online appendix Table 1, avail-
able at http://dx.doi.org/10.2337/db08-0569). Individuals
with one or two T-alleles had the highest HRs of develop-
ing type 2 diabetes if they were obese and had low HDL,
followed by individuals with any one of these two risk
factors and lowest among those with none of the traits
(Table 4). Homozygous individuals (TT) with two meta-
bolic risk factors had the highest HR of type 2 diabetes
(6.04 [95% CI 3.70–9.87] in African Americans and 9.35
[6.72–13.00] in Caucasians) compared with CC individuals
with none of these two. A similar trend was observed for
risk differences and risks of type 2 diabetes (online
TABLE 2
Genotypic frequency of TCF7L2 rs7903146 presented by race and incident type 2 diabetes status, cumulative incidence of type
2 diabetes by race and genotype over 9 years of follow-up, and estimated HRs of rs7903146 on type 2 diabetes by race: the ARIC
study*
African American Caucasian
Genotype Controls/cases
Cumulative
incidence (%)
(95% CI) HR (95% CI)† P‡ Controls/cases
Cumulative
incidence (%)
(95% CI) HR (95% CI)† P‡
n 2,242/485 20.6 (18.7–22.5) 8379/923 10.7 (10.0–11.4)
CC 1,156 (52)/225 (46) 11.3 (10.2–12.4) 1.00 4,295 (51)/430 (47) 9.7 (8.8–10.6) 1.00
CT 921 (41)/212 (44) 21.1 (20.8–21.4) 1.17 (1.02–1.34) 0.03 3,391 (40)/392 (42) 11.3 (10.2–12.4) 1.18 (1.07–1.30) 0.01
TT 165 (7)/48 (10) 27.9 (19.3–36.5) 1.36 (1.03–1.79) 693 (8)/101(11) 13.6 (11.1–16.1) 1.38 (1.14–1.68)
T-allele (%) 28/32 29/32
*The Genotypic distributions were in agreement with Hardy-Weinberg equilibrium in African Americans and Caucasians. †Adjusted for age
at baseline, study center, and sex. ‡P value for HR from additive models.
TABLE 3
Association of TCF7L2 rs7903146 with type 2 diabetes modiﬁed by obesity and low HDL cholesterol over 9 years of follow-up in
ARIC*
Characteristics
HR (95% CI) †
ICR (95% CI) P‡ CC genotype CT genotype TT genotype
African-American
Obesity
No 1 1.32 (1.08–1.61) 1.74 (1.16–2.61) 
0.05 (
0.66 to 0.57) 0.88
Yes 2.91 (2.25–3.76) 3.18 (2.49–4.07) 3.48 (2.44–4.95)
Low HDL
No 1 1.05 (0.87–1.26) 1.10 (0.77–1.58) 0.57 (0.18–0.96) 0.004
Yes 1.45 (1.12–1.88) 2.07 (1.66–2.58) 2.96 (2.08–4.20)
Caucasian
Obesity
No 1 1.21 (1.06–1.37) 1.45 (1.12–1.88) 0.69 (0.10–1.27) 0.02
Yes 3.55 (2.96–4.25) 4.44 (3.76–5.25) 5.56 (4.30–7.19)
Low HDL
No 1 1.20 (1.03–1.40) 1.44 (1.06–1.96) 0.27 (
0.11 to 0.66) 0.16
Yes 2.67 (2.21–3.21) 3.14 (2.64–3.74) 3.69 (2.91–4.69)
*All subgroups had sample sizes of 59 and 141 in African Americans and Caucasians, respectively. †Adjusted for age at baseline, study
center, and sex. ‡P value for ICR.
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effect measure modiﬁer was studied separately, a larger
ICR for obesity (P  0.02) in Caucasians and a larger ICR
for low HDL cholesterol (P  0.004) in African Americans
were observed (Table 3), but testing by bootstrapping (25)
did not support signiﬁcant racial differences (online ap-
pendix A).
DISCUSSION
TCF7L2 has been implicated as an important type 2
diabetes susceptibility gene in different populations. Our
study replicates the association between the T-allele at
rs7903146 and type 2 diabetes risk in Caucasians and
provides the ﬁrst signiﬁcant evidence of association in a
large population-based study of an African American pop-
ulation (4–6,8,). The rs7903146 polymorphism was signif-
icantly associated with type 2 diabetes risk in two other
African-ancestry studies (4,6), but none of these two
studies were population based. Our study also contributes
new evidence for additive interaction between TCF7L2
variants and obesity (P  0.02) in Caucasians and HDL
cholesterol (P  0.004) in African Americans (Table 3).
Indeed, we demonstrate that the risk of developing type 2
diabetes associated with this TCF7L2 variant is substan-
tially increased in the context of some of these well-known
metabolic risk factors for type 2 diabetes.
When studied separately, the most prominent additive
interaction with genotype, indicated by larger ICRs, was
for low HDL in African Americans and obesity in Cauca-
sians (Table 3). To our knowledge, no interaction has been
reported between low HDL and rs7903146. A multiplica-
tive interaction with obesity and high BMI was observed in
two previous studies (8,10). Both studies found that the
risk of type 2 diabetes increased in lean individuals,
whereas no signiﬁcant association was noted in obese or
overweight individuals, suggesting that the SNP rs7903146
is a much more inﬂuential risk factor for lean individuals
than for obese individuals. However, in our study the effect
in obese Caucasians appears slightly stronger than the
effect in lean Caucasians (HR for CT vs. CC 1.25 [1.08–
1.45] in obese individuals and 1.20 [1.05–1.36] in nonobese
individuals), which is discrepant from the ﬁndings of
previous studies. The differences in study populations
(Caucasian vs. Japanese and men/women vs. men only),
analysis methods (additive vs. multiplicative interactions),
study designs (cohort vs. case/control and different inclu-
sion/exclusion criteria) may explain these study discrep-
ancies. Moreover, the mechanism of action of TCF7L2
variants in the context of obesity or other metabolic
impairments needs to be studied further.
The majority of current literature suggests that TCF7L2
is associated with impaired insulin secretion but not with
increased insulin resistance (5,26,27). We found a slightly
lower fasting insulin and HOMA-IR concentration among
individuals with the T-(risk) allele, suggestive of impaired
insulin secretion. A possible explanation of our study
ﬁndings is that TCF7L2 may impair -cell function, which,
when combined with insulin resistance caused by other
factors, provides a double hit that disproportionately
increases the risk for type 2 diabetes. Our study demon-
strates that the risk of type 2 diabetes was substantially
increased among rs7903146 T-allele carriers with obesity
and low HDL cholesterol in comparison with those CC
individuals with HDL in the normal range who were lean
(online appendix Table 2). There is strong evidence that
abnormal metabolic traits including obesity and dyslipide-
mia aggregate in type 2 diabetic patients and their relatives
(28,29). Genetic factors interacting with shared and unique
environmental factors may cause this aggregation of met-
abolic traits (28). Although our study has implicated, for
the ﬁrst time, interesting relationships between these
metabolic risk factors, the TCF7L2 variants, and type 2
diabetes, the mechanism of action of TCF7L2 variants on
type 2 diabetes remains to be determined.
In conclusion, our study provides important new evi-
dence for an association between TCF7L2 and type 2
diabetes in a large African American population. We also
provide estimates of the predicted cumulative incidence of
type 2 diabetes over 9 years of follow-up associated with
this genetic variant in the context of metabolic impair-
ments that usually precede and coexist with type 2 diabe-
tes. Our study ﬁndings need to be replicated in other
population-based studies, and further study is needed on
the mechanisms by which the TCF7L2 gene acts in the
context of metabolic traits in the pathogenesis of type 2
diabetes.
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